Skip to main content
. 2018 Sep 5;184(2):215–222. doi: 10.1111/bjh.15552

Table 1.

Baseline characteristics by cohort

FL = 41 LPL/WM = 17 MZL = 17 MCL = 39 Total = 114
Male, n (%) 20 (48·8) 11 (64·7) 11 (64·7) 25 (64·1) 67 (58·8)
Median age, years (range) 67 (41–89) 72 (47–89) 65 (52–83) 72 (49–92) 71 (41–92)
Median prior therapies, n (range) 3 (1–14) 3 (1–8) 3 (1–8) 2 (1–6) 3 (1–14)
Anti‐CD20 antibody, n (%) 41 (100) 17 (100) 16 (94·1) 37 (94·9) 111 (97·4)
Any alkylating agent, n (%) 39 (95·1) 12 (70·6) 14 (82·4) 37 (94·9) 102 (89·5)
Bendamustine 21 (51·2) 4 (23·5) 10 (58·8) 17 (43·6) 52 (45·6)
Any purine analogue, n (%) 2 (4·9) 4 (23·5) 6 (35·3) 4 (10·3) 16 (14)
Fludarabine 2 (4·9) 3 (17·6) 6 (35·3) 3 (7·7) 14 (12·3)
Anthracyclines, n (%) 21 (51·2) 1 (5·9) 3 (17·6) 30 (76·9) 55 (48·2)

FL, Follicular lymphoma; LPL/WM, Lymphoplasmacytoid lymphoma/Waldenström macroglobulinaemia; MCL, Mantle cell lymphoma; MZL, Marginal zone lymphoma.